BACKGROUND: Microsatellite instability (MSI) is an emerging actionable phenotype in oncology that informs tumor response to immune checkpoint pathway immunotherapy. However, there remains a need for MSI diagnostics that are low cost, highly accurate, and generalizable across cancer types. We developed a method for targeted high-throughput sequencing of numerous microsatellite loci with pan-cancer informativity for MSI using single-molecule molecular inversion probes (smMIPs). METHODS: We designed a smMIP panel targeting 111 loci highly informative for MSI across cancers. We developed an analytical framework taking advantage of smMIP-mediated error correction to specifically and sensitively detect instability events without the need for typing matched normal material. RESULTS: Using synthetic DNA mixtures, smMIPs were sensitive to at least 1% MSI-positive cells and were highly consistent across replicates. The fraction of identified unstable microsatellites discriminated tumors exhibiting MSI from those lacking MSI with high accuracy across colorectal (100% diagnostic sensitivity and specificity), prostate (100% diagnostic sensitivity and specificity), and endometrial cancers (95.8% diagnostic sensitivity and 100% specificity). MSI-PCR, the current standard-of-care molecular diagnostic for MSI, proved equally robust for colorectal tumors but evidenced multiple false-negative results in prostate (81.8% diagnostic sensitivity and 100% specificity) and endometrial (75.0% diagnostic sensitivity and 100% specificity) tumors. CONCLUSIONS: smMIP capture provides an accurate, diagnostically sensitive, and economical means to diagnose MSI across cancer types without reliance on patient-matched normal material. The assay is readily scalable to large numbers of clinical samples, enables automated and quantitative analysis of microsatellite instability, and is readily standardized across clinical laboratories.
BACKGROUND:Microsatellite instability (MSI) is an emerging actionable phenotype in oncology that informs tumor response to immune checkpoint pathway immunotherapy. However, there remains a need for MSI diagnostics that are low cost, highly accurate, and generalizable across cancer types. We developed a method for targeted high-throughput sequencing of numerous microsatellite loci with pan-cancer informativity for MSI using single-molecule molecular inversion probes (smMIPs). METHODS: We designed a smMIP panel targeting 111 loci highly informative for MSI across cancers. We developed an analytical framework taking advantage of smMIP-mediated error correction to specifically and sensitively detect instability events without the need for typing matched normal material. RESULTS: Using synthetic DNA mixtures, smMIPs were sensitive to at least 1% MSI-positive cells and were highly consistent across replicates. The fraction of identified unstable microsatellites discriminated tumors exhibiting MSI from those lacking MSI with high accuracy across colorectal (100% diagnostic sensitivity and specificity), prostate (100% diagnostic sensitivity and specificity), and endometrial cancers (95.8% diagnostic sensitivity and 100% specificity). MSI-PCR, the current standard-of-care molecular diagnostic for MSI, proved equally robust for colorectal tumors but evidenced multiple false-negative results in prostate (81.8% diagnostic sensitivity and 100% specificity) and endometrial (75.0% diagnostic sensitivity and 100% specificity) tumors. CONCLUSIONS: smMIP capture provides an accurate, diagnostically sensitive, and economical means to diagnose MSI across cancer types without reliance on patient-matched normal material. The assay is readily scalable to large numbers of clinical samples, enables automated and quantitative analysis of microsatellite instability, and is readily standardized across clinical laboratories.
Authors: Joseph B Hiatt; Colin C Pritchard; Stephen J Salipante; Brian J O'Roak; Jay Shendure Journal: Genome Res Date: 2013-02-04 Impact factor: 9.043
Authors: Kornelia Neveling; Arjen R Mensenkamp; Ronny Derks; Michael Kwint; Hicham Ouchene; Marloes Steehouwer; Bart van Lier; Ermanno Bosgoed; Alwin Rikken; Marloes Tychon; Dimitra Zafeiropoulou; Steven Castelein; Jayne Hehir-Kwa; Djie Tjwan Thung; Tom Hofste; Stefan H Lelieveld; Stijn M M Bertens; Ivo B J F Adan; Astrid Eijkelenboom; Bastiaan B Tops; Helger Yntema; Tomasz Stokowy; Per M Knappskog; Hildegunn Høberg-Vetti; Vidar M Steen; Evan Boyle; Beth Martin; Marjolijn J L Ligtenberg; Jay Shendure; Marcel R Nelen; Alexander Hoischen Journal: Clin Chem Date: 2016-12-14 Impact factor: 8.327
Authors: Heather Hampel; Wendy Frankel; Jenny Panescu; Janet Lockman; Kaisa Sotamaa; Daniel Fix; Ilene Comeras; Jennifer La Jeunesse; Hidewaki Nakagawa; Judith A Westman; Thomas W Prior; Mark Clendenning; Pamela Penzone; Janet Lombardi; Patti Dunn; David E Cohn; Larry Copeland; Lynne Eaton; Jeffrey Fowler; George Lewandowski; Luis Vaccarello; Jeffrey Bell; Gary Reid; Albert de la Chapelle Journal: Cancer Res Date: 2006-08-01 Impact factor: 12.701
Authors: Kathleen M Murphy; Shengle Zhang; Tanya Geiger; Michael J Hafez; Jeff Bacher; Karin D Berg; James R Eshleman Journal: J Mol Diagn Date: 2006-07 Impact factor: 5.568
Authors: Ludmila Danilova; Hao Wang; Joel Sunshine; Genevieve J Kaunitz; Tricia R Cottrell; Haiying Xu; Jessica Esandrio; Robert A Anders; Leslie Cope; Drew M Pardoll; Charles G Drake; Janis M Taube Journal: Proc Natl Acad Sci U S A Date: 2016-11-11 Impact factor: 11.205
Authors: C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava Journal: Cancer Res Date: 1998-11-15 Impact factor: 12.701
Authors: Zachary R Chalmers; Caitlin F Connelly; David Fabrizio; Laurie Gay; Siraj M Ali; Riley Ennis; Alexa Schrock; Brittany Campbell; Adam Shlien; Juliann Chmielecki; Franklin Huang; Yuting He; James Sun; Uri Tabori; Mark Kennedy; Daniel S Lieber; Steven Roels; Jared White; Geoffrey A Otto; Jeffrey S Ross; Levi Garraway; Vincent A Miller; Phillip J Stephens; Garrett M Frampton Journal: Genome Med Date: 2017-04-19 Impact factor: 11.117
Authors: Mi Ni Huang; John R McPherson; Ioana Cutcutache; Bin Tean Teh; Patrick Tan; Steven G Rozen Journal: Sci Rep Date: 2015-08-26 Impact factor: 4.379
Authors: Paula Martínez-Fernández; Patricia Pose; Raquel Dolz-Gaitón; Arantxa García; Inmaculada Trigo-Sánchez; Enrique Rodríguez-Zarco; MJose Garcia-Ruiz; Ibon Barba; Marta Izquierdo-García; Jennifer Valero-Garcia; Carlos Ruiz; Marián Lázaro; Paula Carbonell; Pablo Gargallo; Carlos Méndez; Juan José Ríos-Martín; Alberto Palmeiro-Uriach; Natalia Camarasa-Lillo; Jerónimo Forteza-Vila; Inés Calabria Journal: J Pers Med Date: 2021-04-29
Authors: Sarabjot Pabla; Jonathan Andreas; Felicia L Lenzo; Blake Burgher; Jacob Hagen; Vincent Giamo; Mary K Nesline; Yirong Wang; Mark Gardner; Jeffrey M Conroy; Antonios Papanicolau-Sengos; Carl Morrison; Sean T Glenn Journal: Oncotarget Date: 2019-08-27
Authors: Elisabeth M P Steeghs; Leonie I Kroeze; Bastiaan B J Tops; Leon C van Kempen; Arja Ter Elst; Annemiek W M Kastner-van Raaij; Sandra J B Hendriks-Cornelissen; Mandy J W Hermsen; Erik A M Jansen; Petra M Nederlof; Ed Schuuring; Marjolijn J L Ligtenberg; Astrid Eijkelenboom Journal: BMC Cancer Date: 2020-04-07 Impact factor: 4.430
Authors: Antoine Daunay; Alex Duval; Laura G Baudrin; Olivier Buhard; Victor Renault; Jean-François Deleuze; Alexandre How-Kit Journal: Nucleic Acids Res Date: 2019-12-02 Impact factor: 16.971